Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EFPIA Trumpets EU-Wide Solution To Drug Theft After Italian Report

This article was originally published in The Pink Sheet Daily

Executive Summary

Europe is largely ignoring drugs theft while focusing on medicines counterfeiting, but a new Italian report could spur stakeholders to unify behind EFPIA's supply chain tracking system.

You may also be interested in...



UK MHRA Starts Internal Review Over Stolen Drug Revelations

The UK MHRA has reacted to a television program on the sale in the UK of medicines stolen in Italy in 2014 by launching an internal review of actions taken at the time. It remains to be seen how effective the EU's new system for detecting falsified medicines will be in preventing the trafficking of stolen drugs. 

European Medicine Authentication System Set To Start By 2019

Starting in January 2016, European countries will have three years to establish medicines verification schemes involving unique serialization numbers on each pack, while the U.K. health secretary now wants drug prices on packs too.

European Notebook: EC Pharma Policy Reorganized; Early Access To Medicines Scheme Starts; U.K. Changing Merger Regs

Changes in responsibilities in new European Commission were welcomed by industry but not by health activists; and a brain cancer vaccine being developed by American biotech is selected to pioneer new early access scheme for innovative drugs being set up in the U.K.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel